View in Other Languages

Imugene Limited

ASX:IMU ISIN:AU000000IMU9

Imugene Limited ASX IMUImugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

     

News

Imugene Limited (ASX:IMU) Encouraging HER-Vaxx Research Published in Prestigious BMC Cancer Journal

🕔2/13/2017 11:14:52 AM 3809

Imugene Limited (ASX:IMU) preclinical research related to HER-Vaxx (clinical name IMU-131) has been accepted and published in the prestigious journal BMC Cancer. IMU-131 is a next generation HER-2 cancer therapy using B cell peptides, which harness the body's ability to develop antibodies against the disease.

Read Full Article

Biotech Investors Move Ahead on the Learning Curve

🕔6/11/2015 3:13:43 PM 8605

Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.

Read Full Article

Australian Market Report of September 16, 2010: Conquest Mining Limited (ASX:CQT) Enters Into Gold-Silver-Copper Offtake Contract with Shandong Guoda Gold

🕔9/16/2010 1:30:08 PM 9275

Australian Market Report of September 16, 2010 inclues; Conquest Mining (ASX:CQT) has entered into an offtake contract for the sale of gold-silver-copper concentrate from its V2 deposit at Mt Carlton, Heemskirk Consolidated Limited (ASX:HSK) has announced the signing of an agreement with Conquest Mining Limited (ASX:CQT), Imugene Limited (ASX:IMU) today announced it has successfully completed a second trial of its Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine and Synthesis Energy Systems Inc. (NASDAQ:SYMX) and Coalworks Limited (ASX:CWK) today made a joint presentation titled "Production of Liquid Fuels from Oaklands Coal Utilizing U-GAS(R) and MTG Technologies".

Read Full Article

IMUGENE LIMITED Biotech Forum<br/>The Road to Commercialisation

🕔2/6/2006 3:45:00 PM 2126

IMUGENE LIMITED Biotech Forum<br/>The Road to Commercialisation; Boardroomradio is pleased to announce that IMUGENE LIMITED (ASX: IMU) has published an audio file. The following presentation "" is now

Read Full Article
###

58,032 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 6) (Last 30 Days: 34) (Since Published: 7988) 

Company Data

    Headquarters
  • Suite 1, 1233 High Street
    Armadale, VIC 3143
    Australia
  • Telephone
  • +61-3-9824-5254 
  • Fax
  • +61-3-9822-7735 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 1993/11/24 
  • Homepage
  • www.imugene.com

Social Media